Tourmaline Bio, Inc.

Shares of $TRML have nearly halved over the past two trading sessions after its rival, Tokyo-based Chugai Pharmaceutical unveiled disappointing results in their own study. Both companies are developing drugs centered around blocking an inflammatory cytokine called IL-6.

Share This Article

 

About the Author

Tourmaline Bio, Inc.

Joey Ramson